Canadian application, no grantCanada
Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
CA 2482919 A1 · Owner: Ruf, Wolfram · Inventors: Riewald, Matthias; Ruf, Wolfram
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to compositions and methods based on the characterization of an endothelial cell protein C receptor (EPCR) dependent signaling by activated protein C (APC) which acts through protease activated receptor 1 (PAR1).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 18, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 18, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 18, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 18, 2003
GrantedNo grant recorded
Term endedApril 18, 2023
Patent numberCA 2482919 A1
Classification (IPC)C12Q1/68 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.